174 related articles for article (PubMed ID: 20832323)
1. c-Met expression is associated with time to recurrence in patients with glioblastoma multiforme.
Liu W; Fu Y; Xu S; Ding F; Zhao G; Zhang K; Du C; Pang B; Pang Q
J Clin Neurosci; 2011 Jan; 18(1):119-21. PubMed ID: 20832323
[TBL] [Abstract][Full Text] [Related]
2. High mobility group A1 expression shows negative correlation with recurrence time in patients with glioblastoma multiforme.
Liu B; Pang B; Liu H; Arakawa Y; Zhang R; Feng B; Zhong P; Murata D; Fan H; Xin T; Zhao G; Liu W; Guo H; Luan L; Xu S; Miyamoto S; Pang Q
Pathol Res Pract; 2015 Aug; 211(8):596-600. PubMed ID: 26092597
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of c-Met expression in glioblastomas.
Kong DS; Song SY; Kim DH; Joo KM; Yoo JS; Koh JS; Dong SM; Suh YL; Lee JI; Park K; Kim JH; Nam DH
Cancer; 2009 Jan; 115(1):140-8. PubMed ID: 18973197
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients.
Wang LF; Fokas E; Bieker M; Rose F; Rexin P; Zhu Y; Pagenstecher A; Engenhart-Cabillic R; An HX
Oncol Rep; 2008 Jan; 19(1):151-6. PubMed ID: 18097589
[TBL] [Abstract][Full Text] [Related]
5. Association between laminin-8 and glial tumor grade, recurrence, and patient survival.
Ljubimova JY; Fugita M; Khazenzon NM; Das A; Pikul BB; Newman D; Sekiguchi K; Sorokin LM; Sasaki T; Black KL
Cancer; 2004 Aug; 101(3):604-12. PubMed ID: 15274074
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
[TBL] [Abstract][Full Text] [Related]
7. Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26).
Vordermark D; Ruprecht K; Rieckmann P; Roggendorf W; Vince GH; Warmuth-Metz M; Kölbl O; Flentje M
BMC Cancer; 2006 Oct; 6():247. PubMed ID: 17049083
[TBL] [Abstract][Full Text] [Related]
8. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.
Chan TA; Weingart JD; Parisi M; Hughes MA; Olivi A; Borzillary S; Alahakone D; Detorie NA; Wharam MD; Kleinberg L
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1133-9. PubMed ID: 15990019
[TBL] [Abstract][Full Text] [Related]
9. Activated ERK1/2 expression in glioblastoma multiforme and in peritumor tissue.
Lama G; Mangiola A; Anile C; Sabatino G; De Bonis P; Lauriola L; Giannitelli C; La Torre G; Jhanwar-Uniyal M; Sica G; Maira G
Int J Oncol; 2007 Jun; 30(6):1333-42. PubMed ID: 17487353
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM).
Combs SE; Widmer V; Thilmann C; Hof H; Debus J; Schulz-Ertner D
Cancer; 2005 Nov; 104(10):2168-73. PubMed ID: 16220556
[TBL] [Abstract][Full Text] [Related]
11. Expression of the Ets-1 proto-oncogene correlates with malignant potential in human astrocytic tumors.
Kitange G; Kishikawa M; Nakayama T; Naito S; Iseki M; Shibata S
Mod Pathol; 1999 Jun; 12(6):618-26. PubMed ID: 10392639
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of c-Met is Associated with Poor Prognosis in Glioblastoma Multiforme: A Systematic Review and Meta-Analyses.
Anton J; Sudibio S; Handoko H; Permata TBM; Kodrat H; Nuryadi E; Sofyan H; Susanto E; Mulyadi R; Aman RA; Gondhowiardjo S
Asian Pac J Cancer Prev; 2021 Oct; 22(10):3075-3080. PubMed ID: 34710981
[TBL] [Abstract][Full Text] [Related]
13. New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials.
Gorlia T; Stupp R; Brandes AA; Rampling RR; Fumoleau P; Dittrich C; Campone MM; Twelves CC; Raymond E; Hegi ME; Lacombe D; van den Bent MJ
Eur J Cancer; 2012 May; 48(8):1176-84. PubMed ID: 22464345
[TBL] [Abstract][Full Text] [Related]
14. Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma.
Santosh V; Arivazhagan A; Sreekanthreddy P; Srinivasan H; Thota B; Srividya MR; Vrinda M; Sridevi S; Shailaja BC; Samuel C; Prasanna KV; Thennarasu K; Balasubramaniam A; Chandramouli BA; Hegde AS; Somasundaram K; Kondaiah P; Rao MR
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1399-408. PubMed ID: 20501753
[TBL] [Abstract][Full Text] [Related]
15. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
[TBL] [Abstract][Full Text] [Related]
16. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.
Choe G; Park JK; Jouben-Steele L; Kremen TJ; Liau LM; Vinters HV; Cloughesy TF; Mischel PS
Clin Cancer Res; 2002 Sep; 8(9):2894-901. PubMed ID: 12231534
[TBL] [Abstract][Full Text] [Related]
17. miR-124a is frequently down-regulated in glioblastoma and is involved in migration and invasion.
Fowler A; Thomson D; Giles K; Maleki S; Mreich E; Wheeler H; Leedman P; Biggs M; Cook R; Little N; Robinson B; McDonald K
Eur J Cancer; 2011 Apr; 47(6):953-63. PubMed ID: 21196113
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
Razis E; Selviaridis P; Labropoulos S; Norris JL; Zhu MJ; Song DD; Kalebic T; Torrens M; Kalogera-Fountzila A; Karkavelas G; Karanastasi S; Fletcher JA; Fountzilas G
Clin Cancer Res; 2009 Oct; 15(19):6258-66. PubMed ID: 19789313
[TBL] [Abstract][Full Text] [Related]
19. Glioblastoma multiforme-report of 267 cases treated at a single institution.
Stark AM; Nabavi A; Mehdorn HM; Blömer U
Surg Neurol; 2005 Feb; 63(2):162-9; discussion 169. PubMed ID: 15680662
[TBL] [Abstract][Full Text] [Related]
20. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.
Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S
Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
